- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03221062
"En Bloc" Resection of NMIBC: a Prospective, Single Centre,Randomized Study
Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Urothelial bladder cancer (UBC) represents a major worldwide healthcare challenge in western countries as well as in developing countries, both oncologically and economically. Initially, most patients present with nonmuscle invasive bladder cancer (NMIBC) with disease confined to the mucosa (stage Ta, carcinoma in situ) or submucosa (T1) characterized by a far lower mortality rate compared with muscle invasive bladder cancer (MIBC).The vast majority of newly diagnosed are non-muscle bladder cancers (NMIBC) which represents about 75% and can be treated with transurethral resection of bladder tumors (TURBT). Therefore, correct initial staging is critical. The quality of TURBT strongly determines patient prognosis and overall treatment.
Conventional transurethral resection of bladder tumors (cTURBT) causes fragmentation. Possible consequences include cell seeding and poor specimen quality, including missing detrusor muscle, thermal tissue damage, and tissue fragmentation. ERBT is developing concept as an alternative to conventional TURBT. En bloc is identified by using various energy sources or modified resection loops as a promising technique. Such as HybridKnife or laser.
The question has been raised as to whether ERBT is ready for guideline implementation. Only two prospective, randomized trials on ERBT have been published. However, there are details on statistical preparation, patient selection, and definitions of primary and secondry goals are missing. Thus, there is still an urgent need to compare ERBT with cTURBT in a thoroughly planned trial.
This study will be conducted in a single centre at Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Eligible patient presented with papillary bladder tumor will be asked to participate in this study and will be provided with an informed consent form in line with Good Clinical Practise and the Declaration of Helsinki.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jia Hu, MD PhD
- Phone Number: +86 13986089626
- Email: jiahutjm@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathological or histological diagnosis by cystoscopy of primary non-muscle invasive bladder urothelial carcinoma (Ta, T1);
- Imaging examinations showed the bladder muscle has not been affected, no lymph node metastasis or distant metastasis;
- Diameter of tumor 1-3cm
- Number of lesions≤3 (The position of small lesions relatively concentrated as one place)
- Patients who agree to ERBT or cTURBT surgery, and will be effected to the postoperative follow-up treatment such as conventional infusion after the operation
Exclusion Criteria:
- Tis or non-transitional epithelial tumors
- Pathological or imaging examinations showed the bladder muscle has not been affected
- There has surgery contraindications, such as bladder fibrosis
- Diameter of tumor >3cm or <1cm
- Number of lesions>3
- Anteriorly located tumor
- Received chemotherapy or BCG perfusion therapy in the nearly 3 months
- Poor performance status is difficult to tolerate surgery
- The patient refused to sign a consent form
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Laser en Bloc Resection
Laser en Bloc Resection of bladder tumor(laser ERBT)
|
Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
Other Names:
|
Experimental: Hydroknife en Bloc Resection
Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
|
Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
Other Names:
|
Experimental: conventional transurethral resection
conventional transurethral resection of bladder tumor(cTURBT)
|
Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The pathological staging assessment
Time Frame: one week
|
The pathological staging assessment for ERBT or cTURBT procedure
|
one week
|
The recurrence rate assessment at resection sites
Time Frame: two year
|
The recurrence rate assessment at resection sites for ERBT or cTURBT procedure
|
two year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
periprocedure complications
Time Frame: 2 days
|
Modified Clavien scale will be used for reporting and comparison of periprocedure complications(obturator nerve reflection;bladder perforation)
|
2 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JHu
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-muscle Invasive Bladder Cancer
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
AstraZenecaHospital Israelita Albert EinsteinRecruitingUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
Huazhong University of Science and TechnologyRecruitingBladder Cancer | Non-Muscle-Invasive Bladder CancerChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)China
-
RenJi HospitalBeiGene; RemeGen Co., Ltd.RecruitingHER2 | Non-Muscle Invasive Bladder CancerChina
-
White River Junction Veterans Affairs Medical CenterMedical University of South Carolina; National Cancer Institute (NCI); University...RecruitingNon-muscle-invasive Bladder CancerUnited States
-
Al-Azhar UniversityRecruiting
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Recruiting
Clinical Trials on Laser en Bloc Resection
-
Mansoura UniversityUnknown
-
University of Kansas Medical CenterRecruitingSurgery | Bladder CancerUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...Unknown
-
Jørgen Bjerggaard JensenNovo Nordisk A/S; University of AarhusRecruitingNon-muscle Invasive Bladder CancerDenmark, Norway, Latvia
-
University of Sao PauloCAIO SERGIO NAHAS; SERGIO CARLOS NAHAS; Ivan Cecconello; Ulysses Ribeiro Junior; Carlos... and other collaboratorsCompleted
-
Chinese University of Hong KongAgilis Robotics LimitedNot yet recruiting
-
Chinese University of Hong KongRecruiting
-
Chinese University of Hong KongThe University of Hong Kong; Queen Elizabeth Hospital, Hong Kong; North District... and other collaboratorsCompleted
-
I.M. Sechenov First Moscow State Medical UniversityUnknownBladder CancerRussian Federation
-
Betul KartalBağcılar Eğitim ve Araştırma HastanesiRecruiting